March 30, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for a new, rapid antigen test that can detect SARS-CoV-2, influenza A and influenza B in a single test.
The BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B assay takes about 15 minutes to run on the BD Veritor Plus System and distinguishes between SARS-CoV-2, influenza A and influenza B, by providing definitive positive or negative individual digital display readouts for all three.
BD plans to launch the new test this summer for the 2021-2022 flu season.
The test is intended for individuals who are suspected by a health care provider of having COVID-19, influenza A or influenza B within six days of symptom onset.
The test follows the same workflow as other rapid tests on the BD Veritor Plus System with a result in about 15 minutes.
The company says there are over 70,000 active BD Veritor Systems in use at hospitals, clinician offices, urgent care centers, nursing homes, retail pharmacies, schools, businesses and other testing locations in all 50 U.S. states.
The BD Veritor System offers customers real-time reporting capabilities through the optional BD Synapsys Informatics Solution, providing them with the ability to easily report data for disease monitoring and surveillance purposes.